instruction
stringlengths 33
156
| input
float64 | output
stringlengths 120
1.97k
|
---|---|---|
Does Abatacept and Cannabidiol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Cannabidiol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Capecitabine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates with a narrow therapeutic index. In short, The metabolism of Capecitabine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Capsaicin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Capsaicin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Carbamazepine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Carbamazepine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Carboplatin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Carboplatin is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Carfilzomib interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Carfilzomib, and the severity of the interaction is major. |
Does Abatacept and Carisoprodol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Carisoprodol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Carmustine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Carmustine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Carvedilol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Carvedilol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Celecoxib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Celecoxib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Celiprolol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Celiprolol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cenobamate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Cenobamate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cephalexin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Cephalexin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ceritinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ceritinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Certolizumab pegol interact? | null | Concomitant use of abatacept and TNF-α inhibitors, which are both immunosuppressive agents, increases the risk of serious infection with no therapeutic benefit. In short, The risk or severity of infection can be increased when Certolizumab pegol is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Cevimeline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Cevimeline can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Chikungunya vaccine (live, attenuated) interact? | null | In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Chlorambucil interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Chloramphenicol interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Chloroquine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Chloroquine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Chlorpheniramine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Chlorpheniramine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Chlorpromazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Chlorpromazine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Chlorpropamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Chlorpropamide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Chlorzoxazone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Chlorzoxazone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ciclesonide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Ciclesonide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cilostazol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Cilostazol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cinacalcet interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Cinacalcet can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cinnarizine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Cinnarizine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cisapride interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Cisapride can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cisplatin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Cisplatin is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Citalopram interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Citalopram can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cladribine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Cladribine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Clarithromycin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Clarithromycin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Clevidipine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Clevidipine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Clindamycin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Clindamycin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Clobazam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Clobazam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Clobetasol propionate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Clofarabine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Clofarabine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Clomipramine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Clomipramine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Clonidine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Clonidine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Clopidogrel interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Clopidogrel can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Clostridium tetani toxoid antigen (formaldehyde inactivated) interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Clotiazepam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Clotiazepam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Clozapine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Clozapine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cobicistat interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Cobicistat can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cobimetinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Cobimetinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Codeine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Codeine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Conivaptan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Conivaptan can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Conjugated estrogens interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Conjugated estrogens can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Copanlisib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Copanlisib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Corticotropin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Corticotropin, and the severity of the interaction is major. |
Does Abatacept and Cortisone acetate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Cortisone acetate, and the severity of the interaction is major. |
Does Abatacept and Crizotinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Crizotinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Cyclobenzaprine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Cyclobenzaprine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Cyclophosphamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates with a narrow therapeutic index. In short, The metabolism of Cyclophosphamide can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Cyclosporine interact? | null | Do not administer cyclosporine with other immunosuppressive agents or radiation therapy (including PUVA and UVB) in patients with psoriasis. The concomitant administration is known to produce excessive immunosuppression. In short, Abatacept may increase the immunosuppressive activities of Cyclosporine, and the severity of the interaction is major. |
Does Abatacept and Cytarabine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Cytarabine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Dabrafenib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates with a narrow therapeutic index. In short, The metabolism of Dabrafenib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Dacarbazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Dacarbazine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Daclatasvir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Daclatasvir can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dacomitinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates with a narrow therapeutic index. In short, The metabolism of Dacomitinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Dactinomycin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Daprodustat interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Daprodustat can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dapsone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Dapsone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Darifenacin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Darifenacin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dasabuvir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Dasabuvir can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dasatinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Dasatinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Daunorubicin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Decitabine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Decitabine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Deflazacort interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Deflazacort, and the severity of the interaction is major. |
Does Abatacept and Denosumab interact? | null | The coadministration of denosumab with immunosuppressive agents poses a high risk of serious infection than with denosumab alone.1,2,3 In short, The risk or severity of adverse effects can be increased when Denosumab is combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Desipramine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Desipramine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Desogestrel interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Desogestrel can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Desoximetasone interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Desvenlafaxine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Desvenlafaxine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Deucravacitinib interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Deucravacitinib, and the severity of the interaction is major. |
Does Abatacept and Deutetrabenazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Deutetrabenazine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dexamethasone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Dexamethasone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dexchlorpheniramine maleate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Dexchlorpheniramine maleate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dexibuprofen interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Dexibuprofen can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dexlansoprazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Dexlansoprazole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dexrazoxane interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Dextroamphetamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Dextroamphetamine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dextromethorphan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Dextromethorphan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dextropropoxyphene interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Dextropropoxyphene can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Diazepam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Diazepam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Diclofenac interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Diclofenac can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Difluocortolone interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Difluocortolone, and the severity of the interaction is major. |
Does Abatacept and Digitoxin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Digitoxin can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Dihydrocodeine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Dihydrocodeine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dihydroergocristine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Dihydroergocristine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dihydroergotamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Dihydroergotamine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Diltiazem interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Diltiazem can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Dimethyl fumarate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Dimethyl fumarate, and the severity of the interaction is major. |
Does Abatacept and Dinutuximab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Dinutuximab, and the severity of the interaction is major. |
Does Abatacept and Diphenhydramine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Diphenhydramine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Diroximel fumarate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Diroximel fumarate, and the severity of the interaction is major. |
Does Abatacept and Disopyramide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Disopyramide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Disulfiram interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Disulfiram can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Docetaxel interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Docetaxel can be increased when combined with Abatacept, and the severity of the interaction is major. |